Psychobiotics: A Paradigm Shift in Dermatological Disorders

Recent clinical studies have demonstrated an intricate bidirectional system in the gut-brain-skin axis. Here, the gut microbiome plays dual roles: it can act as a pathological factor while also serving as a potential therapeutic target in psychodermatology. Chronic skin conditions (CSCs) like acne vulgaris, atopic dermatitis, and psoriasis are some of the leading skin problems. Besides that, these conditions are not only associated with anxiety and depression but also result in a drastic decline in the quality of life. This vicious cycle is due to the combined effects of the host and microbiota. Psychophysiological stress triggers the activation of the hypothalamic-pituitary-adrenal (HPA) axis resulting in increased gut permeability and the systemic translocation of lipopolysaccharide. Subsequent neuroinflammation and the enhanced production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) resulted in the aggravation of skin inflammation. Meanwhile, beneficial gut bacteria (Lactobacillus, Bifidobacterium, Akkermansia, and Faecalibacterium) are a kind of countermeasure to systemic exposure induced by harmful bacteria through the production of short-chain fatty acids (SCFAs). SCFAs tighten intestinal barrier tight junctions, facilitate regulatory T-cell (Treg) function, and, via vagal signaling, generate neuroactive compounds such as GABA and serotonin. Psychobiotics probiotics and prebiotics with specific psychotropic properties propose a revolutionary therapeutic approach by simultaneously addressing the gastrointestinal dysbiosis, the stress-induced elevation of cortisol, and the inflammation of peripheral tissues. Clinical trials have demonstrated that certain strains (e.g., L. rhamnosus SP1, L. plantarum, and L. helveticus) are able to normalize the skin gene expression, reduce the number of lesions, and enhance psychological well-being. Nevertheless, problems related to strain specificity, individual colonization resistance, minimal regulatory supervision, and safety profiles for long-term usage still exist. This paper reviews molecular mechanisms and clinical data that support the development of large-scale, placebo-controlled trials and interdisciplinary approaches to enable psychobiotics as a part of routine, precision dermatological therapy.